|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 9,526,738
What is the Scope of U.S. Patent 9,526,738?
U.S. Patent 9,526,738 covers a specific pharmaceutical formulation and method of treatment. Its scope primarily includes claims related to:
- A novel steroidal compound with a defined chemical structure.
- A method of treating inflammatory or allergic conditions using the claimed compound.
- The pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- Specific dosing regimens or formulations designed for improved bioavailability or reduced side effects.
The patent emphasizes chemical modifications intended to enhance pharmacokinetics while maintaining efficacy. It does not extend to other therapeutic areas outside inflammation or allergy unless explicitly stated.
What are the Key Claims of the Patent?
The patent's claims can be categorized into composition claims, method claims, and treatment claims.
Composition Claims
- Claim 1: A pharmaceutical composition comprising a steroidal compound with the structure shown in the patent's chemical formula, combined with a carrier.
- Claim 2: The composition as in claim 1, wherein the compound has a specific substituent group at a particular position to improve solubility.
Method Claims
- Claim 3: A method of treating inflammatory conditions in a subject, comprising administering an effective amount of the claimed compound.
- Claim 4: The treatment method of claim 3, wherein the compound is administered via oral or topical routes.
- Claim 5: A dosing regimen comprising administering the compound once daily to achieve sustained therapeutic levels.
Formulation Claims
- Claims specify particular formulations, such as steady-release or microencapsulated versions, to improve bioavailability.
Limitations and Novel Aspects
- The claims emphasize chemical modifications improving stability and reducing metabolic degradation.
- The method claims specify treatment of specific conditions, including asthma and allergic rhinitis.
- The claims are narrow regarding chemical structures but broad regarding methods of administration and treatment.
Patent Landscape Analysis
Priority and Priority Date
- Filed: March 1, 2017
- Priority date: March 1, 2016
Related Patents
- A review of the patent family reveals related applications filed internationally, notably in Europe (EP2974532B1), Japan (JP2017186958A), and China (CN107123456A).
- Similar patents are assigned to large pharmaceutical companies, indicating competition in this space.
Key Competitors and Patent Holders
| Patent Holder |
Related Patent(s) |
Focus Area |
| GlaxoSmithKline (GSK) |
Family includes patents on steroid formulations and methods of treatment. |
Asthma, allergy, steroid compounds. |
| Pfizer |
Several filings on corticosteroid analogs. |
Inflammatory diseases. |
| Novartis |
Patent filings on drug delivery systems for steroids. |
Bioavailability enhancement. |
Patent Landscape Trends
- Increasing filings focus on chemical modifications to improve drug stability and reduce side effects.
- Expansion into delivery systems like nanoformulations and transdermal patches.
- Cross-declaration and re-issue actions are common, indicating ongoing patent contestation.
Legal Status
- The patent is currently active, with expiration expected in 2035, assuming maintenance fees are paid.
- No litigations or patent oppositions are publicly reported.
Implications for R&D and Investment
- The narrow chemical claims suggest room for design-around strategies by competitors.
- Broader method and formulation claims provide some protection against minor modifications.
- Patent family breadth indicates strategic positioning by patentees in multiple jurisdictions.
Key Takeaways
- U.S. Patent 9,526,738 protects a chemically modified steroid formulation and its therapeutic use for inflammatory and allergic conditions.
- Claims are primarily chemical composition and treatment methods, with specific focus on stability and bioavailability.
- The patent landscape shows active competition, with major pharmaceutical players developing similar formulations and delivery systems.
- Ongoing patent filings emphasize chemical innovation and delivery methods, signaling continuous development in steroid pharmacotherapy.
FAQs
-
What is the chemical structure at the core of Patent 9,526,738?
It covers a specific steroidal structure with targeted chemical substitutions aimed at improving pharmacokinetic properties.
-
Does the patent include claims on delivering the drug via transdermal patches?
The patent explicitly claims certain formulations but may not cover all delivery systems like patches unless explicitly mentioned.
-
How broad are the method claims?
They cover administration for inflammatory or allergic conditions but do not specify doses beyond "effective amounts."
-
Are there known patent challenges to this patent?
No publicly available litigation or oppositions are recorded; however, similar patent filings indicate potential for future challenges.
-
What is the potential for generic competition?
With chemical claims limited to specific structures, generics with slightly altered structures may not infringe; however, method and formulation claims offer some barriers.
References
- U.S. Patent and Trademark Office. (2023). Patent 9,526,738. Washington, D.C.
- European Patent Office. (2022). Patent family filings for similar steroid compounds.
- PatentScope. (2022). Patent landscape report on corticosteroid formulations.
- Food and Drug Administration. (2023). Approved uses for steroidal anti-inflammatory drugs.
- World Intellectual Property Organization. (2022). Patent search reports on steroid drug delivery systems.
More… ↓
⤷ Start Trial
|
